ストックスクリーナーアプリを入手
35.14
3.23%
1.10
Pharvaris Nv (PHVS) 最新ニュース
Research Analysts Issue Forecasts for Pharvaris Q4 Earnings - MarketBeat
General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership - Stock Titan
PHVS (NASDAQ: PHVS) holder Berndt Modig plans 2,292-share stock sale - Stock Titan
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress - Investing.com
Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions - Kalkine Media
PHVS Maintains Outperform Rating -- Price Target Raised to $52.0 - GuruFocus
Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says - marketscreener.com
PHVS Maintains Rating by Citizens -- Price Target Raised to $75. - GuruFocus
RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating - marketscreener.com
Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com Nigeria
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate - scanx.trade
Pharvaris N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
(PHVS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones - TipRanks
Pharvaris' Q2 Loss Per Share Narrows - marketscreener.com
Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share - marketscreener.com
Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position - Quiver Quantitative
Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date - Stock Titan
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update - Enidnews.com
Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage? - Sahm
Claude AI's Latest Portfolio Additions Spotlight Pharvaris and Micron as Hedge Fund FavoritesROIC Trend Report - dars.gov.et
Pharvaris NV (PHVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pharvaris (NASDAQ:PHVS) Sets New 12-Month HighWhat's Next? - MarketBeat
Pharvaris N.V. (PHVS) Stock Analysis: Unpacking a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Pharvaris NV (PHVS) Stock News Today - TradingKey
Pharvaris publishes study on rare angioedema condition By Investing.com - Investing.com South Africa
Pharvaris publishes study on rare angioedema condition - Investing.com
Painful swelling and misdiagnoses disrupted daily life in Pharvaris study - Stock Titan
Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment (NASDAQ:PHVS) - Seeking Alpha
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run - Yahoo Finance
Pharvaris N.V. $PHVS is Seven Fleet Capital Management LP's 5th Largest Position - MarketBeat
(PHVS) Risk Channels and Responsive Allocation - Stock Traders Daily
Pharvaris N.V. (PHVS) Stock Analysis: A Biotech With 41.23% Potential Upside - DirectorsTalk Interviews
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet - Yahoo Finance
Pharvaris N.V. $PHVS Shares Sold by Eversept Partners LP - MarketBeat
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Octagon Capital Advisors LP Has $4.66 Million Holdings in Pharvaris N.V. $PHVS - MarketBeat
Pharvaris NV (PHVS) Financial Health: Profitability & Balance Sheet Analysis - tradingkey.com
PHVS|Pharvaris NV|Price:34.170|Chg%:+0.910 - TradingKey
PHVS|Pharvaris NV|Price:35.140|Chg%:+1.100 - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Pharvaris Director Sells Shares Worth $1.33 Million - sekbernews.id
Pharvaris N.V. Revenue Breakdown – NASDAQ:PHVS - TradingView
After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over? - The Motley Fool
Pharvaris publishes review on bradykinin B2 receptor research - Investing.com
Pharvaris publishes review on bradykinin B2 receptor research By Investing.com - Investing.com Canada
Here's why Pharvaris NV (PHVS) is a great momentum stock to buy - MSN
(PHVS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Morgan Stanley Maintains Pharvaris N.V. (PHVS) Overweight Recommendation - MSN
Pharvaris N.V. (NASDAQ:PHVS) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy - Yahoo Finance
PHVS Initiated Coverage by Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo initiates Pharvaris stock with Overweight rating - Investing.com
Wells Fargo initiates Pharvaris stock with Overweight rating By Investing.com - Investing.com Canada
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):